Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Acute kidney injury occurs in up to 30% of CAR-T cell-treated patients

Publish date:: June 11, 2020

Key clinical point: Acute kidney injury, mostly grade 1, was seen in nearly 1/3 of CAR-T-cell treated patients.

Major finding: The cumulative incidence of any grade of acute kidney injury by day 100 was 30%.

Study details: A retrospective review of 46 adult patients with non-Hodgkin lymphoma (96% DLBCL) treated with CAR-T therapy between February 2018 and February 2019 at a single institution.

Disclosures: : The study was supported in part by the National Institutes of Health. The authors reported consulting and research funding from a variety of pharmaceutical companies.

Citation:

Gutarts V et al. Biology of Blood and Marrow Transplantation. 2020 ;26(6) 1071-6.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,